Xencor, Inc. XNCR

Company Overview

Xencor, Inc. is a publicly traded clinical-stage biotechnology company focused on the discovery and development of engineered monoclonal antibodies and cytokines for the treatment of cancer and immune-related diseases. The company operates within the biopharmaceutical and biotechnology industries, with core expertise in protein engineering technologies that enhance the efficacy, safety, and half-life of antibody-based therapeutics.

Xencor’s primary value is derived from its proprietary XmAb® antibody engineering platform, which is used both for internal drug candidates and for partnered programs with large pharmaceutical companies. The company was founded in 1997 and has evolved from a technology-licensing model into a diversified pipeline developer with multiple internally developed clinical-stage programs, while continuing to generate revenue through collaborations, milestones, and royalties.